Answers are grounded in this paper and cite their sources.
Tumor types and novel molecular alterations are being described at an accelerating rate, leading to rapid evolution of the classification system. There have been several recent developments in the classification of superficial fibroblastic and myofibroblastic tumor types, and, accordingly, there have been newly discovered pitfalls relevant to dermatopathology. Here, we survey new developments in the diagnosis and molecular pathogenesis of fibroblastic and myofibroblastic neoplasms of the skin and subcutis. Plexiform myofibroblastoma is a benign tumor type with plexiform architecture that can mimic the more aggressive plexiform fibrohistiocytic tumor. PLAG1 -rearranged fibromyxoid tumor is possibly related to lipoblastoma, occurs in superficial sites, and can mimic low-grade fibromyxoid sarcoma and spindle cell rhabdomyosarcoma. Superficial ALK -rearranged myxoid spindle cell neoplasm is a recently described cutaneous tumor type that can be mistaken for dermatofibrosarcoma protuberans (DFSP), and recent evidence suggests it is on a biologic spectrum with epithelioid fibrous histiocytoma. Similarly, plaque-like CD34-positive dermal fibroma and related NTRK - or ALK- rearranged plaque-like dermal neoplasms represent an expanding group of superficially located CD34-positive spindle cell tumors that may mimic DFSP. Nodular necrotizing fibroblastic tumor is a recently described, typically indolent tumor type that often occurs in skin and subcutis, harbors YAP1 :: MAML2 fusions, and closely mimics myxoinflammatory fibroblastic sarcoma. In addition to these new entities, we discuss some likely under-recognized tumor types that present pitfalls, including fibroblastic connective tissue nevus, which can mimic DFSP, and superficial CD34-positive pleomorphic fibroblastic tumor, which can mimic pleomorphic sarcoma. Collectively, these entities necessitate integrated histologic, immunohistochemical, and, sometimes, molecular evaluation to ensure accurate diagnosis and to avoid overtreatment.
No takes yet. Share an insight, caveat, or question.
Draper et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: